Dr. Tore Bengtsson is a professor of molecular bioscience at Stockholm University’s Wenner‑Gren Institute, where he investigates metabolic signalling in muscle cells. His research emphasizes novel therapies—such as lab‑engineered β₂‑agonists—that enhance fat burning while preserving muscle mass and improving blood sugar control. He co-led a study published in Cell demonstrating that this approach could offer a safer, injection‑free alternative for treating type 2 diabetes and obesity.